Xu Ye

Guangzhou, China

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 18 publications

Olverembatinib (HQP1351)-based therapy in adults with relapsed or refractory Philadelphia chromosome-positive acute lymphoblastic leukemia or chronic myeloid leukemia in blast phase: results from a real-world study.

Olverembatinib (HQP1351)-based therapy in adults with relapsed or refractory Philadelphia chromosome-positive acute lymphoblastic leukemia or chronic myeloid leukemia in blast phase: results from a real-world study.

Journal: Frontiers in immunology
Published: December 16, 2024

Chidamide, a Histone Deacetylase Inhibitor, Combined With R-GemOx in Relapsed/Refractory Diffuse Large B-Cell Lymphoma (TRUST): A Multicenter, Single-Arm, Phase 2 Trial.

Chidamide, a Histone Deacetylase Inhibitor, Combined With R-GemOx in Relapsed/Refractory Diffuse Large B-Cell Lymphoma (TRUST): A Multicenter, Single-Arm, Phase 2 Trial.

Journal: Cancer medicine
Published: November 22, 2024

Vedolizumab plus basiliximab as second-line therapy for steroid-refractory lower gastrointestinal acute graft-versus-host disease.

Vedolizumab plus basiliximab as second-line therapy for steroid-refractory lower gastrointestinal acute graft-versus-host disease.

Journal: Frontiers in immunology
Published: March 27, 2024

Bendamustine in the treatment of patients with indolent non-Hodgkin lymphoma refractory or relapse to rituximab treatment: An open-label, single-agent, multicenter study in China.

Bendamustine in the treatment of patients with indolent non-Hodgkin lymphoma refractory or relapse to rituximab treatment: An open-label, single-agent, multicenter study in China.

Journal: Cancer
Published: June 08, 2022

Ibrutinib as monotherapy versus combination therapy in Chinese patients with relapsed/refractory mantle cell lymphoma: A multicenter study.

Ibrutinib as monotherapy versus combination therapy in Chinese patients with relapsed/refractory mantle cell lymphoma: A multicenter study.

Journal: Cancer medicine
Published: September 02, 2021

Prognostic significance of FSCN family in multiple myeloma.

Prognostic significance of FSCN family in multiple myeloma.

Journal: Journal of Cancer
Published: September 24, 2020

Prognostic significance of Spinster homolog gene family in acute myeloid leukemia.

Prognostic significance of Spinster homolog gene family in acute myeloid leukemia.

Journal: Journal of Cancer
Published: February 10, 2020

High expression of chaperonin-containing TCP1 subunit 3 may induce dismal prognosis in multiple myeloma.

High expression of chaperonin-containing TCP1 subunit 3 may induce dismal prognosis in multiple myeloma.

Journal: The pharmacogenomics journal
Published: November 21, 2019

Prognostic significance of the PANK family expression in acute myeloid leukemia.

Prognostic significance of the PANK family expression in acute myeloid leukemia.

Journal: Annals of translational medicine
Published: July 30, 2019

High EGFL7 expression may predict poor prognosis in acute myeloid leukemia patients undergoing allogeneic hematopoietic stem cell transplantation.

High EGFL7 expression may predict poor prognosis in acute myeloid leukemia patients undergoing allogeneic hematopoietic stem cell transplantation.

Journal: Cancer biology & therapy
Published: July 16, 2019

Upregulation of Glutamic-Oxaloacetic Transaminase 1 Predicts Poor Prognosis in Acute Myeloid Leukemia.

Upregulation of Glutamic-Oxaloacetic Transaminase 1 Predicts Poor Prognosis in Acute Myeloid Leukemia.

Journal: Frontiers in oncology
Published: July 15, 2019

Up-regulation of DDIT4 predicts poor prognosis in acute myeloid leukaemia.

Up-regulation of DDIT4 predicts poor prognosis in acute myeloid leukaemia.

Journal: Journal of cellular and molecular medicine
Published: July 02, 2019
Showing 1-12 of 18

Last Updated: 09/26/2026